Genflow Biosciences Share Discussion Threads

[olly353] 13/4/2023 12:03

Buy quote now 3.588

[olly353] 13/4/2023 11:58

Huge spread now unlike earlier. Think they are trying put breaks on alittle. Can sell no problem but can't get a buy quote.

[felchandbart] 13/4/2023 11:52

Well, hello. Off we go! Another big move afoot by the looks of things.

[olly353] 13/4/2023 11:37

Real bid is 3.12 which is above the shown mid price....

[olly353] 13/4/2023 10:47

Trying to crack 3 now....

[felchandbart] 12/4/2023 11:54

Looking pretty solid again today. I don't tend to throw the kitchen sink at shares but GENF looks like a company that's on the cusp of delivering spectacular returns for investors. Have added.

[blackhorse23] 12/4/2023 01:06

Bankrupt company? Switched to HARL

[olly353] 11/4/2023 11:22

Only been watching this for couple of weeks now but great volume today far..

[stark industries] 11/4/2023 10:57

Here's why this UK BioTech stock could potentially be set to rise imminently

Authored by Joe Neighbour (MSTA)

Joe started his career in financial services with HSBC at 18 years old before moving into broking arena at several small to medium-size firms. It was here that Joe gained vast experience in dealing with high net worth individuals and providing wealth solutions.

He began to develop a passion for technical analysis and this desire to learn more about markets sent him down a path of trading. Joe became involved in trading markets just before the 2008 financial crisis and had to quickly adapt to some very challenging conditions.

Joe is a Member of the Society of Technical Analysis (MSTA) and Chartered Fellow (CISI). He has 15+ years’ experience in financial markets across a variety of roles including broking, portfolio managing, and analysis.

Today I’m going to tell you about a revolutionary biotech startup that I previously tipped when it was trading at 2p back in November.

A company I believe is set to explode and has the potential to rise significantly in the near term.

What justifies such a bold prediction?



This company may hold the keys to the cure for aging...

The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.

Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*

The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.

But before I go any further, let me ask you something…

Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?

According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.

With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.

But backing from big names isn’t the only ace up the sleeve of Altos Labs…

The company has built an executive dream team of industry experts and scientific luminaries.

Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.



What is reprogramming and why is it important you might ask?

Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.

Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?

Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.

With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”



But what does all of this have to do with Genflow Biosciences potentially significant rise in value?

I’m going to tell you, but first, let’s get some background.

Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).

Okay, but why should we expect such sudden exponential growth.

The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...

To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.



But even the companies regarded as the cream-of-crop are at a disadvantage…

They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”

Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.

This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…

If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.

Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.

It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.

Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price



News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.

This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.

That is why I am recommending readers take a close look at it right now.

The company is currently eyeing a listing in other markets and a US listing may be on the horizon.



If I were to bet on the next big biotech stock story, Genflow BioSciences would be it.

[felchandbart] 06/4/2023 10:06

On a roll this morning. Perhaps the penny has dropped about how ridiculously cheap this is.

[northeast14] 05/4/2023 18:39

Absolute bargain this. ERIC has stated this will be a Billion £/$ share. Well that’s £3 a share. Not bad at all

[felchandbart] 05/4/2023 10:55

Being quoted 2.24 for even 20000 currently. Definite upward momentum. This could now be one of the shares of the year.

[photon] 05/4/2023 09:46

This company is looking interesting. Microcap, no apparent funding needs next 12 months, pipeline high potential if a little "out there". I was at a big corporate that took a punt on sirtuins that failed, however GENF seem to have some intriguing results in SIRT6.. maybe the pipeline will have longevity too..

[jakes114] 09/3/2023 11:09

When is there a chance of news they just keep drifting down on low volume??

[moneymunch] 23/2/2023 08:59

Definitely blue!!! Gla :-)

[tomboyb] 22/2/2023 10:59

may go blue -

[moneymunch] 03/1/2023 08:35

Genflow has a wealth of transformational opportunities in the US...ho ho ho...Gla holders....2023 could be a great year for those invested in Genflow, especially from this rockbottom bargain low!!! :-)



Genflow’s focus is on the Sirtuin 6 gene, or SIRT6 for short, which is seen as ‘master regulator of healthy ageing’.

It targets four of the nine ‘hallmarks of ageing’ rather than single facets that are the preserve of other drug candidates. 

The company’s R&D effort leans very heavily into the research carried out by Dr Vera Gorbunova at the University of Rochester in the US, who is also on the company’s scientific advisory board.

[moneymunch] 22/12/2022 08:43

or maybe a Bed & ISA given the difference in sp's.

[goldensharewolf] 21/12/2022 09:50

They aren't buys they are T20 rollovers

[moneymunch] 20/12/2022 12:36

2 x 1.9m buys!!! Looking forward to a transformational year ahead. Gla :-)

[moneymunch] 14/12/2022 07:27

It's all good , amazing prospects and potential for transformational UPSIDE!!! Gla :-)